ECSP23095307A - Agonista del receptor de glp-1 y composición y uso del mismo - Google Patents

Agonista del receptor de glp-1 y composición y uso del mismo

Info

Publication number
ECSP23095307A
ECSP23095307A ECSENADI202395307A ECDI202395307A ECSP23095307A EC SP23095307 A ECSP23095307 A EC SP23095307A EC SENADI202395307 A ECSENADI202395307 A EC SENADI202395307A EC DI202395307 A ECDI202395307 A EC DI202395307A EC SP23095307 A ECSP23095307 A EC SP23095307A
Authority
EC
Ecuador
Prior art keywords
glp
composition
receptor agonist
receptor
disorders
Prior art date
Application number
ECSENADI202395307A
Other languages
English (en)
Inventor
Zhe Wang
Wenqiang Zhai
Liubin Guo
Zhimin Zhang
Qian Wang
Hao Pan
Original Assignee
Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd filed Critical Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd
Publication of ECSP23095307A publication Critical patent/ECSP23095307A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona un compuesto agonista del receptor de GLP-1 y una composición y uso del mismo. El compuesto puede utilizarse para tratar o prevenir enfermedades o trastornos mediados por el receptor de GLP-1 y enfermedades o trastornos relacionados. (II)
ECSENADI202395307A 2021-06-24 2023-12-19 Agonista del receptor de glp-1 y composición y uso del mismo ECSP23095307A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110702643 2021-06-24

Publications (1)

Publication Number Publication Date
ECSP23095307A true ECSP23095307A (es) 2024-01-31

Family

ID=84544137

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202395307A ECSP23095307A (es) 2021-06-24 2023-12-19 Agonista del receptor de glp-1 y composición y uso del mismo

Country Status (14)

Country Link
US (1) US11981666B2 (es)
EP (1) EP4361145A1 (es)
KR (1) KR20240024910A (es)
CN (2) CN117098758A (es)
AU (1) AU2022300055A1 (es)
CA (1) CA3219984A1 (es)
CL (1) CL2023003794A1 (es)
CO (1) CO2023017726A2 (es)
CR (1) CR20230611A (es)
DO (1) DOP2023000275A (es)
EC (1) ECSP23095307A (es)
IL (1) IL309235A (es)
TW (1) TW202317553A (es)
WO (1) WO2022268152A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2716664C (en) 2008-03-07 2016-10-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds
AU2010232750B2 (en) 2009-03-30 2015-10-29 Vtv Therapeutics Llc Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
EP3352750A4 (en) 2015-11-04 2018-08-01 Hyundai Pharm Co., Ltd. Cyclohexene derivative, preparation method thereof, and pharmaceutical composition for preventing or treating metabolic disease comprising the same as active ingredient
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
PE20191501A1 (es) 2016-12-16 2019-10-22 Pfizer Agonistas receptores de glp-1 y sus usos de los mismos
KR101910586B1 (ko) 2017-03-03 2018-10-23 한국화학연구원 헤테로아릴이 치환된 2-페닐이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 GLP-1 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
CU20210042A7 (es) * 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
MA55627A (fr) * 2019-04-12 2022-02-16 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
CR20220178A (es) * 2019-10-25 2022-06-15 Gilead Sciences Inc Compuestos moduladores de glp-1r
JP2023515404A (ja) * 2020-02-13 2023-04-13 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環ｇｌｐ－１アゴニスト
US11851419B2 (en) * 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds

Also Published As

Publication number Publication date
TW202317553A (zh) 2023-05-01
CN117098758A (zh) 2023-11-21
US11981666B2 (en) 2024-05-14
AU2022300055A1 (en) 2024-01-18
CA3219984A1 (en) 2022-12-29
CR20230611A (es) 2024-02-19
EP4361145A1 (en) 2024-05-01
KR20240024910A (ko) 2024-02-26
CN117362283A (zh) 2024-01-09
DOP2023000275A (es) 2024-02-15
CO2023017726A2 (es) 2024-02-15
IL309235A (en) 2024-02-01
WO2022268152A1 (zh) 2022-12-29
CL2023003794A1 (es) 2024-05-24
US20240116906A1 (en) 2024-04-11

Similar Documents

Publication Publication Date Title
CO2022006183A2 (es) Agonista del receptor glp-1 y uso de este
PE20191474A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
DOP2021000273A (es) Agonistas del receptor del péptido-1 similar al glucagón
CO2023003322A2 (es) Compuestos como agonistas de glp-1r
CO2019005924A2 (es) Agonistas duales acilados de glp-1/glp-2
CO2021017401A2 (es) Agonistas de receptor de melanocortina-4
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
UY37098A (es) Moduladores de ror-gamma
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2019001465A1 (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip.
CL2012003053A1 (es) Combinacion farmaceutica que comprende un agonista del receptor glp-1 y linagliptin, inhibidor dpp-4; uso de la combinacion farmaceutica para el tratamiento de la diabetes tipo 2 y de la obesidad.
UY37505A (es) Conjugados que comprenden un agonista dual de glp-1/glucagón, un conector y ácido hialurónico
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
CL2008002096A1 (es) Combinacion farmaceutica que comprende un antagonista del receptor vanilloide vr-1 y un antiinflamatorio no esteroidal o una sal o solvato de cualquiera o de ambos compuestos; composicion farmaceutica que comprende dicha combinacio; y su uso de la combinacion para tratar un trastorno mediado por ek receptor vainilloide vr1.
CL2021001753A1 (es) Compuestos derivados de 2,4-diaminoquinazolina; composición farmacéutica; y su uso para el tratamiento de una infección vírica, cáncer, entre otras (divisional de solicitud 202002253).
CL2017002913A1 (es) Tratamiento de la hipoglucemia posbariátrica con exendina (9-39)
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
ECSP19062381A (es) Moduladores del receptor de estrógeno
UY38958A (es) Agonista del receptor glp-1 y uso de este
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer
CL2021001884A1 (es) Compuestos heterocíclicos como antagonistas de la adenosina.
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
CL2021000184A1 (es) Piridopirimidinas como inhibidores del receptor de histamina h4
ECSP23095307A (es) Agonista del receptor de glp-1 y composición y uso del mismo